La reinserción laboral y la reanudación de las tareas del hogar suponen el último paso en la superación del cáncer de mama (CM). evaluar si las características clínicas y el tipo de tratamiento afectan de forma negativa el desempeño en el puesto de trabajo y en el hogar. se incluyeron 119 pacientes diagnosticadas de CM precoz. Se midieron las variables laborales y las relacionadas con las tareas del hogar. al ser diagnosticadas, la mayoría de las pacientes tenía trabajo y realizaba las tareas del hogar. A los dos años de finalizado el tratamiento, el 50% de las pacientes que trabajaban continuaba trabajando y el 68.6% de estas tuvieron dificultades para retomar su trabajo. Las pacientes que no retomaron su actividad laboral fueron diagnosticadas en estadios más avanzados y tuvieron más complicaciones postoperatorias (p < 0.005). En cuanto a la ejecución de las tareas del hogar, el 83.3% tuvieron algún grado de dificultad para llevarlas a cabo. Las pacientes que fueron sometidas a vaciamiento axilar ganglionar, las que recibieron más frecuentemente apoyo psicológico y las que tuvieron más complicaciones postoperatorias realizaron las tareas del hogar con mayor esfuerzo (p < 0.005). una vez terminado el tratamiento, el 50% de las pacientes no se reincorporó a su actividad laboral. En este caso, se objetivó el efecto negativo del estadio y de las complicaciones postoperatorias (p < 0.005). Estos datos revelan que la reinserción laboral tras el diagnóstico y tratamiento del CM es complicada.
HER-2 positive (+) breast cancer (BC) accounts for 20-25% of BC, it is more aggressive, and it has a lower survival rate. Since the approval of trastuzumab in 1998, other HER-2-targeted therapies such as pertuzumab and trastuzumab emtansine (TDM1) have been introduced, improving patient survival. However, cardiotoxicity is an adverse effect of these treatments. To estimate the incidence of cardiotoxicity with trastuzumab, trastuzumab/pertuzumab, and TDM1 in women with HER-2 + BC treated over a 6-year period at the Hospital de Clínicas and the Hospital Departamental de Soriano. Observational, descriptive, and retrospective study which included patients with HER-2 + BC treated with trastuzumab, trastuzumab/pertuzumab, or TDM1. 81 patients were included, with a cardiotoxicity incidence of 23.4%. Cardiotoxicity was determined by a > 10% decrease in left ventricular ejection fraction (LVEF) (57.9%) and a LVEF < 50% evident during treatment (42.1%). Only 1 patient presented symptomatic heart failure. 63.1% of those who discontinued treatment due to cardiotoxicity managed to resume it. No relationship was evident between cardiovascular history or the administration regimen and the development of cardiotoxicity. The study showed a cardiotoxicity incidence similar to the international one. Most did not present cardiac toxicity, and if they did, it was asymptomatic and reversible.
Male breast cancer (MBC) is a rare condition which, while sharing some similarities with breast cancer in women, has a unique disease profile of its own. Aim: To understand the characteristics of M...
Introduction Advances in treatment have improved the survival rates of patients diagnosed with breast cancer. However, the number of women experiencing long-term consequences has also increased, affecting their quality of life, including sexual function. Objectives To evaluate the prevalence of sexual dysfunction as measured by the Female Sexual Function Index, its association with treatment modalities in Uruguayan breast cancer survivors, and to compare the questionnaire scores by age group (50 years or older versus under 50 years). Methods This ambispective observational study included patients diagnosed with early-stage breast cancer (I to III) who had completed surgery, chemotherapy, and radiotherapy treatments at least 12 months before inclusion. Patients completed the Female Sexual Function Index questionnaire, and the data were analyzed using simple and multiple binary logistic models to assess the relationship between treatment modalities and sexual dysfunction. Additionally, differences in Female Sexual Function Index scores between age groups were analyzed. Results A total of 149 patients were included; 67.1% underwent breast-conserving surgery, 68.5% received chemotherapy, 92.6% radiotherapy, and 95.3% hormone therapy. Sexual dysfunction, defined as a score ≤ 26.55 on the questionnaire, was present in 58.3% of patients. Multivariate analysis indicated a higher risk of sexual dysfunction in patients who underwent total mastectomy, were treated with chemotherapy, or used gonadotropin-releasing hormone agonists. Conclusions Although this study highlights the impact of certain treatment modalities on sexual function, the results should be interpreted considering the characteristics of the population and potential biases. These findings can guide clinicians in planning treatments to improve the quality of life of sexually active breast cancer patients.
3 June 2026 in European Journal of Medical and Health Research
Immune checkpoint inhibitors have transformed the treatment of advanced melanoma; however, they may be associated with potentially severe immune-related adverse events. Among these, myocarditis–myositis– myasthenia overlap syndrome (MMM) is a rare but highly life-threatening condition. We report the case of an 84-year-old patient with stage IV melanoma treated with nivolumab and ipilimumab using a reduced-dose regimen, who initially developed immune-mediated hepatitis, followed by proximal muscle weakness, bulbar involvement, and myasthenic symptoms, associated with markedly elevated creatine kinase levels. During hospitalization, the patient developed complete atrioventricular block and significant troponin elevation, consistent with MMM overlap syndrome. Treatment with high-dose intravenous methylprednisolone followed by oral corticosteroids and pyridostigmine was initiated, resulting in favorable clinical evolution, with neurological improvement and hemodynamic stabilization without the need for second-line therapies. This case highlights the importance of early recognition of severe immune- related adverse events, the need for a multidisciplinary approach, and prompt initiation of immunosuppressive therapy, which may significantly improve clinical outcomes even in elderly patients.
Background/Aim: Adjuvant hormone therapy (HT) significantly improves survival in patients with hormone receptor-positive breast cancer, yet adherence to this therapy is critical and tends to decrease over time. This study aims to identify risk factors for suboptimal adherence to adjuvant HT among patients treated at the Hospital de Clínicas and the Hospital Departamental de Soriano, Uruguay, to inform future strategies to improve adherence. Materials and Methods: A retrospective, cross-sectional study was conducted, including 96 breast cancer patients in stages I-III treated with HT for at least three years. Adherence was assessed using the Morisky-Green questionnaire. Statistical analysis was employed to estimate the odds ratios (OR) for non-adherence, with a significance threshold of α=0.05. Results: Out of the 96 patients included, 22.9% demonstrated suboptimal adherence to hormone therapy. Analysis revealed that the use of tamoxifen (adjusted OR of 4.86, p<0.05) and living with others were significant predictors of non-adherence. The aggressiveness of the treatment did not show a statistically significant correlation with adherence. Additionally, the analysis highlighted that sociodemographic characteristics, such as marital status and employment situation, did not directly influence adherence, underscoring the complexity of factors contributing to treatment adherence. Intriguingly, the analysis showed a trend towards greater adherence among postmenopausal patients and those with a history of combined treatment of tamoxifen and aromatase inhibitors, though these results warrant further exploration. Conclusion: Suboptimal adherence to adjuvant HT in breast cancer patients is significantly influenced by the type of hormone therapy prescribed and the patient's social environment. It is necessary to develop personalized interventions that address these factors to improve adherence.